DÄ internationalArchive41/2006Statin Treatment in Coronary Heart Disease

Review article

Statin Treatment in Coronary Heart Disease

Dtsch Arztebl 2006; 103(41): A-2714

Laufs, U; Hamm, C; Böhm, M

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

1. Stamler J, Wentworth D, Neaton J, for the MRFIT Research Group: Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256: 2823–8. MEDLINE
2. Baigent C, Keech A, Kearney PM et al.: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–78. MEDLINE
3. National Cholesterol Education Program Expert Panel: Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). National Heart, Lung, and Blood Institute, National Institutes of Health, Publication No 02-5215. 2002; 3143–421.
4. Gohlke H, Kübler W, Mathes P et al.: Positionspapier zur Primärprävention kardiovaskulärer Erkrankungen. Z Kardiol 2003; 522–4. MEDLINE
5. Arznei­mittel­kommission der Deutschen Ärzteschaft (www.akdae.de). Therapieempfehlung Fettstoffwechselstörungen. Köln: Deutscher Ärzte-Verlag 2002; 169–89.
6. Dietz R, Rauch B: Leitlinie zur Diagnose und Behandlung der chronischen koronaren Herzerkrankung der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung (DGK). Z Kardiol 2003; 92: 501–21. MEDLINE
7. de Backer G, Ambrosioni E, Borch-Johnsen K et al.: European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003; 10: S1–10. MEDLINE
8. Ärztliches Zentrum für Qualität in der Medizin. Nationale Versorgungs-Leitlinie „Chronische KHK“. www versorgungsleitlinien de. 2006.
9. Grundy SM, Cleeman JI, Merz CN et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227–39. MEDLINE
10. Donner-Banzhoff N, Popert U, Laufs U: Lipidsenkung mit Statinen – Titration oder feste Dosis. Dtsch Arztebl 2004; 101: 1649–51.
11. Arznei­mittel­kommission der deutschen Ärzteschaft (Hrsg.): Koronare Herzkrankheit. Arzneiverordnungen 21. Auflage, Köln: Deutscher Ärzte-Verlag 2006.
12. Gibbons RJ, Abrams J, Chatterjee K et al.: ACC/AHA 2002 guideline update for the management of patients with chronic stable angina-summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2003; 41: 159–68. MEDLINE
13. Mosca L, Appel LJ, Benjamin EJ et al.: Evidence-based guidelines for cardiovascular disease prevention in women. American Heart Association scientific statement. Arterioscler Thromb Vasc Biol 2004; 24: e29–50. MEDLINE
14. Schwartz GG, Olsson AG, Ezekowitz MD et al.: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001; 285: 1711–8. MEDLINE
15. Cannon CP, Braunwald E, McCabe CH et al.: Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495–504. MEDLINE
16. de Lemos JA, Blazing MA, Wiviott SD et al.: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292: 1307–16. MEDLINE
17. LaRosa JC, Grundy SM, Waters DD et al.: Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425–35. MEDLINE
18. Koren MJ, Hunninghake DB: Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. J Am Coll Cardiol 2004; 44: 1772–9. MEDLINE
19. Nissen SE, Tuzcu EM, Schoenhagen P et al.: Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291: 1071–80. MEDLINE
20. Pedersen TR, Faergeman O, Kastelein JJ et al.: High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294: 2437–45. MEDLINE
21. Scandinavian Simvastatin Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–9. MEDLINE
22. Liao JK, Laufs U: Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89–118. MEDLINE
23. Istvan ES, Deisenhofer J: Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001; 292: 1160–4. MEDLINE
24. Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature 1990; 343: 425–30. MEDLINE
25. Pasternak RC, Smith SC, Jr., Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C: ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 2002; 106: 1024–8.
e1. Landmesser U, Bahlmann F, Mueller M et al.: Simvastatin versusezetimibe: pleiotropic and lipid-lowering effects on endothelial functionin humans. Circulation 2005; 111: 2356–63. MEDLINE

Info

Specialities